CN102516408A - 一种玻璃酸钠的纯化方法 - Google Patents
一种玻璃酸钠的纯化方法 Download PDFInfo
- Publication number
- CN102516408A CN102516408A CN2011103884392A CN201110388439A CN102516408A CN 102516408 A CN102516408 A CN 102516408A CN 2011103884392 A CN2011103884392 A CN 2011103884392A CN 201110388439 A CN201110388439 A CN 201110388439A CN 102516408 A CN102516408 A CN 102516408A
- Authority
- CN
- China
- Prior art keywords
- complex
- precipitation
- hyaluronic acid
- acid sodium
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 title claims abstract description 33
- 238000000746 purification Methods 0.000 title claims abstract description 17
- 238000000034 method Methods 0.000 title abstract description 11
- 229920002385 Sodium hyaluronate Polymers 0.000 title abstract 4
- 229940010747 sodium hyaluronate Drugs 0.000 title abstract 4
- 238000001556 precipitation Methods 0.000 claims abstract description 44
- 239000000243 solution Substances 0.000 claims abstract description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 18
- 238000003756 stirring Methods 0.000 claims abstract description 18
- 239000006228 supernatant Substances 0.000 claims abstract description 13
- 239000002244 precipitate Substances 0.000 claims abstract description 9
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 8
- 239000007864 aqueous solution Substances 0.000 claims abstract description 7
- 239000007788 liquid Substances 0.000 claims abstract description 7
- 238000007865 diluting Methods 0.000 claims abstract description 6
- 238000002156 mixing Methods 0.000 claims abstract description 6
- 238000005406 washing Methods 0.000 claims abstract description 6
- 238000001179 sorption measurement Methods 0.000 claims abstract description 5
- 239000000706 filtrate Substances 0.000 claims abstract description 4
- 238000010494 dissociation reaction Methods 0.000 claims description 26
- 230000005593 dissociations Effects 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 241000561734 Celosia cristata Species 0.000 claims description 10
- 238000010521 absorption reaction Methods 0.000 claims description 10
- 239000003610 charcoal Substances 0.000 claims description 10
- 210000001520 comb Anatomy 0.000 claims description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 230000000536 complexating effect Effects 0.000 claims description 8
- 230000008021 deposition Effects 0.000 claims description 7
- 239000008213 purified water Substances 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 230000018044 dehydration Effects 0.000 claims description 2
- 238000006297 dehydration reaction Methods 0.000 claims description 2
- 239000012535 impurity Substances 0.000 abstract description 5
- 239000000047 product Substances 0.000 abstract description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 3
- 229960001927 cetylpyridinium chloride Drugs 0.000 abstract 2
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 abstract 2
- 238000001914 filtration Methods 0.000 abstract 2
- 206010067484 Adverse reaction Diseases 0.000 abstract 1
- 238000002835 absorbance Methods 0.000 abstract 1
- 230000006838 adverse reaction Effects 0.000 abstract 1
- 230000001376 precipitating effect Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 8
- 235000014347 soups Nutrition 0.000 description 7
- 230000003287 optical effect Effects 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 238000000605 extraction Methods 0.000 description 4
- 150000003839 salts Chemical group 0.000 description 4
- 239000002253 acid Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- HLLSOEKIMZEGFV-UHFFFAOYSA-N 4-(dibutylsulfamoyl)benzoic acid Chemical group CCCCN(CCCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 HLLSOEKIMZEGFV-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- CKMXBZGNNVIXHC-UHFFFAOYSA-L ammonium magnesium phosphate hexahydrate Chemical compound [NH4+].O.O.O.O.O.O.[Mg+2].[O-]P([O-])([O-])=O CKMXBZGNNVIXHC-UHFFFAOYSA-L 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 125000000600 disaccharide group Chemical group 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000012262 fermentative production Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 159000000000 sodium salts Chemical group 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229910052567 struvite Inorganic materials 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Landscapes
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110388439 CN102516408B (zh) | 2011-11-29 | 2011-11-29 | 一种玻璃酸钠的纯化方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110388439 CN102516408B (zh) | 2011-11-29 | 2011-11-29 | 一种玻璃酸钠的纯化方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102516408A true CN102516408A (zh) | 2012-06-27 |
CN102516408B CN102516408B (zh) | 2013-12-18 |
Family
ID=46287517
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201110388439 Expired - Fee Related CN102516408B (zh) | 2011-11-29 | 2011-11-29 | 一种玻璃酸钠的纯化方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102516408B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103819579A (zh) * | 2013-12-10 | 2014-05-28 | 上海景峰制药股份有限公司 | 一种玻璃酸钠的干燥方法 |
CN103880982A (zh) * | 2013-12-10 | 2014-06-25 | 上海景峰制药股份有限公司 | 一种提高玻璃酸钠含量的方法 |
CN106883319A (zh) * | 2017-04-28 | 2017-06-23 | 上海景峰制药有限公司 | 一种降低蛋白质含量的玻璃酸钠的制备方法 |
CN106883320A (zh) * | 2017-04-28 | 2017-06-23 | 上海景峰制药有限公司 | 一种降低蛋白质含量的玻璃酸钠的二次解离制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102134287A (zh) * | 2010-01-22 | 2011-07-27 | 上海昊海生物科技股份有限公司 | 一种管道化鸡冠提取玻璃酸钠(透明质酸钠)的制备方法 |
-
2011
- 2011-11-29 CN CN 201110388439 patent/CN102516408B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102134287A (zh) * | 2010-01-22 | 2011-07-27 | 上海昊海生物科技股份有限公司 | 一种管道化鸡冠提取玻璃酸钠(透明质酸钠)的制备方法 |
Non-Patent Citations (1)
Title |
---|
陈涛等: "酶解条件对透明质酸提取及其分子量分布的影响", 《中国医药工业杂志》, vol. 42, no. 11, 10 November 2011 (2011-11-10), pages 808 - 711 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103819579A (zh) * | 2013-12-10 | 2014-05-28 | 上海景峰制药股份有限公司 | 一种玻璃酸钠的干燥方法 |
CN103880982A (zh) * | 2013-12-10 | 2014-06-25 | 上海景峰制药股份有限公司 | 一种提高玻璃酸钠含量的方法 |
CN103819579B (zh) * | 2013-12-10 | 2017-01-04 | 上海景峰制药股份有限公司 | 一种玻璃酸钠的干燥方法 |
CN106883319A (zh) * | 2017-04-28 | 2017-06-23 | 上海景峰制药有限公司 | 一种降低蛋白质含量的玻璃酸钠的制备方法 |
CN106883320A (zh) * | 2017-04-28 | 2017-06-23 | 上海景峰制药有限公司 | 一种降低蛋白质含量的玻璃酸钠的二次解离制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102516408B (zh) | 2013-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101935362B (zh) | 预铺助滤剂纯化透明质酸的方法 | |
CN101550199B (zh) | 一种从透明质酸发酵液中制备透明质酸钠的方法 | |
CN102516408B (zh) | 一种玻璃酸钠的纯化方法 | |
CN103214595B (zh) | 硫酸软骨素钠的制备方法 | |
CN108484794A (zh) | 一种透明质酸季铵基衍生物及其制备和纯化方法 | |
CN101948494B (zh) | 一种腺苷钴胺提取方法 | |
CN101633701B (zh) | 一种透明质酸的纯化方法 | |
CN110683970B (zh) | 一种从牛磺酸中去除硫酸钠固体杂质的方法 | |
CN102552906A (zh) | 静注人免疫球蛋白的生产工艺 | |
CN108467345B (zh) | 一种从蒜头果中提取神经酸的方法及神经酸包合物 | |
CN105949348A (zh) | 一种透明质酸分子量分级方法 | |
CN103183743A (zh) | 一种葫芦脲[6]接枝壳聚糖的制备方法 | |
CN103012470A (zh) | 利用菜籽粕制备液体植酸的方法 | |
CN114990586B (zh) | 一种金刚烷基三甲基氢氧化铵的制备工艺及其制备的季铵碱水溶液 | |
CN101993503B (zh) | 一种粉末状透明质酸钠的制备方法 | |
CN111635402A (zh) | 吡咯喹啉醌的分离纯化方法 | |
CN104610466A (zh) | 一种降低生物提取法制备玻璃酸钠中蛋白质含量的方法及制备的玻璃酸钠 | |
CN110734505A (zh) | 一种羧甲基甲壳素的制备方法 | |
CN103421128A (zh) | 一种高品质低分子帕那肝素的制备方法 | |
CN1200005C (zh) | 右旋糖酐的生产方法 | |
CN102584611B (zh) | 一种药用级缬氨酸的生产方法 | |
CN105906816B (zh) | 一种键接灯盏花乙素阳离子聚轮烷及其制备方法和应用 | |
CN102276751B (zh) | 一种从泥螺中提取糖胺聚糖的方法 | |
CN109336990B (zh) | 一种质子化氨基石墨烯脱除植物多糖色素的方法及应用 | |
CN110327371B (zh) | 碳酸氢钠林格注射液及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: 200120 Shanghai city Baoshan District Luo Road No. 50 Patentee after: SHANGHAI JINGFENG PHARMACEUTICAL Co.,Ltd. Address before: 200120 Shanghai city Baoshan District Luo Road No. 50 Patentee before: SHANGHAI JINGFENG PHARMACEUTICAL Co.,Ltd. |
|
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: 200120 Shanghai city Baoshan District Luo Road No. 50 Patentee after: SHANGHAI JINGFENG PHARMACEUTICAL Co.,Ltd. Address before: 200120 Shanghai city Baoshan District Luo Road No. 50 Patentee before: SHANGHAI JINGFENG PHARMACEUTICAL Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20131218 |